Is there evidence for cannabis in migraine and headache disorders?
Research-Based Answer
Migraine is one of the conditions most frequently cited in the clinical endocannabinoid deficiency hypothesis — migraine patients have lower CSF anandamide levels than controls. The trigeminal pain pathway, central to migraine pathophysiology, is modulated by CB1 receptors. Survey and observational evidence: a 2019 study (Aviram & Samuelly-Leichtag) found medical cannabis reduced migraine frequency from 10.4 to 4.6 headaches/month. A 2020 retrospective study found inhaled cannabis aborted acute migraine attacks in 94% of users. A 2021 study found cannabis comparable to ibuprofen for acute migraine pain. RCT evidence: a 2017 study compared a THC:CBD combination to amitriptyline for migraine prevention — the cannabinoid combination reduced migraine frequency by 40.4% vs. 40.1% for amitriptyline (not significantly different). Limitations: all studies are observational or have methodological weaknesses; medication overuse headache (rebound headache) is a concern with frequent cannabis use for migraine; no large, well-designed RCTs exist.
This answer summarizes peer-reviewed research and is intended for educational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before making any medical decisions.